Drug
JNJ-87801493
JNJ-87801493 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Enrolling by invitation1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
enrolling_by_invitation133%
recruiting133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
enrolling_by_invitationphase_1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509
recruitingphase_1
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT07308132
active_not_recruitingphase_1
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406
Clinical Trials (3)
Showing 3 of 3 trials
NCT06788509Phase 1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT07308132Phase 1
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT06139406Phase 1
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3